"Virus Potentiation of Tumor Vaccine T-Cell Stimulatory Capacity Requires Cell Surface Binding But Not Infection."

According to the authors' abstract of an article published in Clinical Cancer Research, "This study elucidates a basically new mechanism of function of a virus-modified tumor cell vaccine which has been successful in mouse tumor models (metastatic ESb lymphoma and B16-F10 melanoma) in preventing or delaying metastatic spread and improving survival and which is being tested in clinical studies. Modification of tumor cells by a low dose of Newcastle disease virus (NDV), which caused this therapy effect, led to an augmentation of the tumor-specific cytotoxic CD8 T-cell (CTL) response and to increased CD4 T-helper activity in the absence of an antiviral T-cell response. When various...

Want to see the full article?

• Purchase this article for only $3.00